Prostate-specific Antigen (PSA), Ultrasensitive (Serial Monitor)
Use
This test is intended for use as an aid in the management of patients following surgical or medical treatment for prostate cancer. It involves long-term serial monitoring of PSA levels, providing color graphic summary reports to assist in tracking changes in PSA levels over time. According to the American Urological Association, serum PSA should decrease and remain at undetectable levels after radical prostatectomy. Biochemical recurrence is defined as an initial PSA value 0.200 ng/mL or greater followed by a subsequent confirmatory PSA value 0.200 ng/mL or greater.
Special Instructions
The account must submit the patient's Social Security number for serial monitoring. PSA sampling should not be performed for at least six weeks after prostatic biopsy. Values obtained with different assay methods should not be used interchangeably in serial testing. Only one assay method should be used consistently to monitor each patient's course of therapy. To order this test without the serial monitor service, use test 140731.
Limitations
Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. Only consistent use of the same assay method is recommended for reliable monitoring.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 35741-8
- 35741-8
- 80563-0
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Not provided.